Castle Biosciences (NASDAQ: CSTL) CEO gains 62,219 shares from PSU vesting
Rhea-AI Filing Summary
Castle Biosciences reported that President and CEO Derek J. Maetzold received equity awards tied to performance. On January 12, 2026, 62,219 performance-based stock units (PSUs) granted on March 4, 2024 vested after the board certified that specific performance criteria were met. Each PSU converts into one share of common stock, so Maetzold acquired 62,219 shares of common stock at $0 per share, bringing his directly held common stock to 91,732 shares.
The filing also lists additional common stock held indirectly through various family and grantor retained annuity trusts for estate and family planning purposes. A remaining block of 62,219 PSUs from the 2024 grant is still outstanding and will vest only if stated milestones are achieved.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance-Based Stock Unit | 62,219 | $0.00 | -- |
| Grant/Award | Common Stock | 62,219 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents 50% of the Performance-Based Stock Units ("PSUs") granted on March 4, 2024 ("2024 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on January 12, 2026. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones.
FAQ
What insider transaction did CSTL report for Derek Maetzold?
Castle Biosciences reported that President and CEO Derek J. Maetzold had 62,219 performance-based stock units vest on January 12, 2026, resulting in the acquisition of 62,219 shares of common stock at $0 per share.
What are the 2024 performance-based stock units mentioned for CSTL?
The filing describes 2024 PSUs granted on March 4, 2024. Half of these PSUs, totaling 62,219 units, vested after performance criteria were certified as satisfied, and each unit delivered one share of common stock.
How many performance-based stock units remain unvested for the CSTL CEO?
The filing states that the reported PSUs represent 50% of the 2024 PSUs. The remaining 50%, equal to 62,219 PSUs, will vest only upon achievement of specified milestones.
Does this CSTL Form 4 reflect any insider stock sales?
No sales are reported. The transactions described are acquisitions at $0 per share resulting from the vesting of performance-based stock units and updated beneficial ownership positions.